DB:XCY

Stock Analysis Report

Executive Summary

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally.

Rewards

Trading at 82.4% below its fair value

Revenue is forecast to grow 10.12% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Has less than 1 year of cash runway

Shareholders have been diluted in the past year



Snowflake Analysis

Fair value with imperfect balance sheet.


Similar Companies

Share Price & News

How has OPKO Health's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: XCY has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-0.9%

XCY

0.4%

DE Biotechs

0.2%

DE Market


1 Year Return

-41.0%

XCY

9.0%

DE Biotechs

14.4%

DE Market

Return vs Industry: XCY underperformed the German Biotechs industry which returned 7.2% over the past year.

Return vs Market: XCY underperformed the German Market which returned 14.1% over the past year.


Shareholder returns

XCYIndustryMarket
7 Day-0.9%0.4%0.2%
30 Day6.1%-2.1%0.9%
90 Day5.4%8.0%4.6%
1 Year-41.0%-41.0%9.2%9.0%17.9%14.4%
3 Year-82.0%-82.0%45.5%43.9%15.7%5.6%
5 Year-88.6%-88.6%12.8%10.5%23.4%6.5%

Price Volatility Vs. Market

How volatile is OPKO Health's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is OPKO Health undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: XCY (€1.46) is trading below our estimate of fair value (€8.33)

Significantly Below Fair Value: XCY is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: XCY is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: XCY is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate XCY's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: XCY is good value based on its PB Ratio (0.6x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is OPKO Health forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

45.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: XCY is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: XCY is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: XCY is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: XCY's revenue (10.1% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: XCY's revenue (10.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if XCY's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has OPKO Health performed over the past 5 years?

-20.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: XCY is currently unprofitable.

Growing Profit Margin: XCY is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: XCY is unprofitable, and losses have increased over the past 5 years at a rate of -20.6% per year.

Accelerating Growth: Unable to compare XCY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: XCY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: XCY has a negative Return on Equity (-16.97%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is OPKO Health's financial position?


Financial Position Analysis

Short Term Liabilities: XCY's short term assets ($292.8M) exceed its short term liabilities ($270.1M).

Long Term Liabilities: XCY's short term assets ($292.8M) do not cover its long term liabilities ($457.5M).


Debt to Equity History and Analysis

Debt Level: XCY's debt to equity ratio (16.5%) is considered satisfactory.

Reducing Debt: XCY's debt to equity ratio has increased from 14.7% to 16.5% over the past 5 years.


Balance Sheet

Inventory Level: XCY has a low level of unsold assets or inventory.

Debt Coverage by Assets: XCY's debt is covered by short term assets (assets are 1.1x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: XCY has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if XCY has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is OPKO Health's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate XCY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate XCY's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if XCY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XCY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of XCY's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.9yrs

Average management tenure


CEO

Phil Frost (83yo)

12.9yrs

Tenure

US$2,036,000

Compensation

Dr. Phillip Frost, also known as Phil, M.D., Ph.D., has been Chief Executive Officer of Opko Health, Inc. since March 27, 2007. Dr. Frost serves as the Managing Director and General Partner of Frost Philli ...


CEO Compensation Analysis

Compensation vs Market: Phil's total compensation ($USD2.04M) is above average for companies of similar size in the German market ($USD1.17M).

Compensation vs Earnings: Phil's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Phillip Frost
Chairman & CEO12.9yrsUS$2.04m0.46% $4.5m
Jane Hsiao
Vice Chairman & Chief Technical Officer12.8yrsUS$1.98m3.68% $35.9m
Adam Logal
Senior VP & CFO5.9yrsUS$1.25m0.027% $263.1k
Steven Rubin
Executive VP of Administration & Director13yrsUS$1.46m0.86% $8.4m
Kate Inman
General Counsel & Secretary0yrsno datano data
Arie Gutman
President of API0yrsno datano data
James DeMarco
Senior Vice President of Pharmaceutical Sales3.8yrsno datano data
Thomas Nusbickel
Chief Commercial Officer3.8yrsno datano data
Akhtar Ashfaq
Senior Vice President of Clinical Research & Development and Medical Affairs2.9yrsno datano data
Jon Cohen
Senior Vice President1.1yrsno datano data

5.9yrs

Average Tenure

64yo

Average Age

Experienced Management: XCY's management team is seasoned and experienced (5.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Phillip Frost
Chairman & CEO12.9yrsUS$2.04m0.46% $4.5m
Jane Hsiao
Vice Chairman & Chief Technical Officer12.8yrsUS$1.98m3.68% $35.9m
Steven Rubin
Executive VP of Administration & Director13yrsUS$1.46m0.86% $8.4m
Jon Cohen
Senior Vice President1.1yrsno datano data
Richard Pfenniger
Independent Director12.1yrsUS$95.00k0.041% $403.8k
Richard Lerner
Independent Director & Member of Scientific Advisory Board12.9yrsUS$70.00k0.030% $292.0k
John Paganelli
Independent Director16.2yrsUS$75.00k0.055% $541.1k
Roger Kornberg
Member of Scientific Advisory Board0yrsno datano data
Lin-Tsing Yu
Independent Director10.8yrsUS$60.00k0.010% $97.6k
Robert Fishel
Independent Director1.8yrsUS$112.21k0.62% $6.1m

12.8yrs

Average Tenure

72yo

Average Age

Experienced Board: XCY's board of directors are seasoned and experienced ( 12.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.2%.


Top Shareholders

Company Information

OPKO Health, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: OPKO Health, Inc.
  • Ticker: XCY
  • Exchange: DB
  • Founded: 1991
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.055b
  • Listing Market Cap: US$977.226m
  • Shares outstanding: 665.60m
  • Website: https://www.opko.com

Number of Employees


Location

  • OPKO Health, Inc.
  • 4400 Biscayne Boulevard
  • Miami
  • Florida
  • 33137
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XCYDB (Deutsche Boerse AG)YesCommon StockDEEURNov 1995
OPKNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDNov 1995
OPK *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNNov 1995
OPKTASE (The Tel-Aviv Stock Exchange)YesCommon StockILILSNov 1995
0KCSLSE (London Stock Exchange)YesCommon StockGBUSDNov 1995

Biography

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company’s Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The company’s Pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, a selective androgen receptor modulator for benign prostatic hyperplasia, and other urologic and metabolic conditions; and OPK88003, a once or twice weekly oxyntomodulin that is in Phase II trials for type 2 diabetes and obesity. It is also developing hGH-CTP, a once-weekly human growth hormone injection in Phase III clinical trial in partnership with Pfizer, Inc.; VARUBI for chemotherapy-induced nausea and vomiting; and Factor VIIa drug for hemophilia. In addition, this segment develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, it develops, manufactures, markets, and sells pharmaceutical, nutraceutical, and veterinary products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro- intestinal products, hormones, and others. Additionally, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/19 21:36
End of Day Share Price2020/02/19 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.